Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

An NHS surgeon has delivered his 'hot take' on why weight-loss jabs like Wegovy and Mounjaro are causing 'Ozempic babies' to be born.

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...